Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

846 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Role of Deficient DNA Mismatch Repair Status in Patients With Stage III Colon Cancer Treated With FOLFOX Adjuvant Chemotherapy: A Pooled Analysis From 2 Randomized Clinical Trials.
Zaanan A, Shi Q, Taieb J, Alberts SR, Meyers JP, Smyrk TC, Julie C, Zawadi A, Tabernero J, Mini E, Goldberg RM, Folprecht G, Van Laethem JL, Le Malicot K, Sargent DJ, Laurent-Puig P, Sinicrope FA. Zaanan A, et al. Among authors: tabernero j. JAMA Oncol. 2018 Mar 1;4(3):379-383. doi: 10.1001/jamaoncol.2017.2899. JAMA Oncol. 2018. PMID: 28983557 Free PMC article.
Current issues in adjuvant treatment of stage II colon cancer.
André T, Sargent D, Tabernero J, O'Connell M, Buyse M, Sobrero A, Misset JL, Boni C, de Gramont A. André T, et al. Among authors: tabernero j. Ann Surg Oncol. 2006 Jun;13(6):887-98. doi: 10.1245/ASO.2006.07.003. Epub 2006 Apr 14. Ann Surg Oncol. 2006. PMID: 16614880 Review.
Phase III trial of capecitabine plus oxaliplatin as adjuvant therapy for stage III colon cancer: a planned safety analysis in 1,864 patients.
Schmoll HJ, Cartwright T, Tabernero J, Nowacki MP, Figer A, Maroun J, Price T, Lim R, Van Cutsem E, Park YS, McKendrick J, Topham C, Soler-Gonzalez G, de Braud F, Hill M, Sirzén F, Haller DG. Schmoll HJ, et al. Among authors: tabernero j. J Clin Oncol. 2007 Jan 1;25(1):102-9. doi: 10.1200/JCO.2006.08.1075. J Clin Oncol. 2007. PMID: 17194911 Clinical Trial.
Phase II trial of cetuximab in combination with fluorouracil, leucovorin, and oxaliplatin in the first-line treatment of metastatic colorectal cancer.
Tabernero J, Van Cutsem E, Díaz-Rubio E, Cervantes A, Humblet Y, André T, Van Laethem JL, Soulié P, Casado E, Verslype C, Valera JS, Tortora G, Ciardiello F, Kisker O, de Gramont A. Tabernero J, et al. J Clin Oncol. 2007 Nov 20;25(33):5225-32. doi: 10.1200/JCO.2007.13.2183. J Clin Oncol. 2007. PMID: 18024868 Clinical Trial.
Phase I pharmacokinetic/pharmacodynamic study of EKB-569, an irreversible inhibitor of the epidermal growth factor receptor tyrosine kinase, in combination with irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) in first-line treatment of patients with metastatic colorectal cancer.
Folprecht G, Tabernero J, Köhne CH, Zacharchuk C, Paz-Ares L, Rojo F, Quinn S, Casado E, Salazar R, Abbas R, Lejeune C, Marimón I, Andreu J, Ubbelohde U, Cortes-Funes H, Baselga J. Folprecht G, et al. Among authors: tabernero j. Clin Cancer Res. 2008 Jan 1;14(1):215-23. doi: 10.1158/1078-0432.CCR-07-1053. Clin Cancer Res. 2008. PMID: 18172273 Clinical Trial.
Oxaliplatin-based chemotherapy in the management of colorectal cancer.
Capdevila J, Elez E, Peralta S, Macarulla T, Ramos FJ, Tabernero J. Capdevila J, et al. Among authors: tabernero j. Expert Rev Anticancer Ther. 2008 Aug;8(8):1223-36. doi: 10.1586/14737140.8.8.1223. Expert Rev Anticancer Ther. 2008. PMID: 18699761 Review.
The role of salvage treatment in advanced colorectal cancer.
Capdevila J, Ramos FJ, Macarulla T, Elez E, Tabernero J. Capdevila J, et al. Among authors: tabernero j. Crit Rev Oncol Hematol. 2009 Jul;71(1):53-61. doi: 10.1016/j.critrevonc.2008.09.006. Epub 2008 Nov 1. Crit Rev Oncol Hematol. 2009. PMID: 18977669 Review.
Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3.
Van Cutsem E, Labianca R, Bodoky G, Barone C, Aranda E, Nordlinger B, Topham C, Tabernero J, André T, Sobrero AF, Mini E, Greil R, Di Costanzo F, Collette L, Cisar L, Zhang X, Khayat D, Bokemeyer C, Roth AD, Cunningham D. Van Cutsem E, et al. Among authors: tabernero j. J Clin Oncol. 2009 Jul 1;27(19):3117-25. doi: 10.1200/JCO.2008.21.6663. Epub 2009 May 18. J Clin Oncol. 2009. PMID: 19451425 Clinical Trial.
Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial.
André T, Boni C, Navarro M, Tabernero J, Hickish T, Topham C, Bonetti A, Clingan P, Bridgewater J, Rivera F, de Gramont A. André T, et al. Among authors: tabernero j. J Clin Oncol. 2009 Jul 1;27(19):3109-16. doi: 10.1200/JCO.2008.20.6771. Epub 2009 May 18. J Clin Oncol. 2009. PMID: 19451431 Clinical Trial.
846 results